WHO WE ARE
Litmys combines customer insights, analytical rigor, and extensive commercial experience to help life science leadership teams and investors make better decisions before committing to costly late‑stage trials or sales and marketing spend.
Our proprietary demand‑driven approach consistently and rapidly drives adoption, sales, and share for your pharmaceutical, biotech, or medical device product, helping you get it right the first time.
WHY LITMYS
Litmys combines seasoned expertise with practical insight, we know what works and why. Our approach is built on years of experience, delivering solutions that are both effective and durable.
125+
$300B+
PRODUCT
LAUNCHES
PRODUCT PEAK SALES
50+
55+
200M+
SATISFIED
CLIENTS
YEARS TOTAL
EXPERIENCE
LIVES COVERED IN OUR PAYER PANEL
THE CHALLENGE
Product Approval
≠
Market Adoption
Across the industry, half of new pharmaceutical products fail to meet their forecasts, not due to approvability, but because they lack meaningful differentiation. Today’s hurdles? Payer restrictions, physician reluctance, and patient hesitancy. Advancing into costly late‑stage trials without testing the probability of adoption is a coin‑flip that today’s portfolios can’t afford.
WHAT LITMYS
DOES
Litmys reduces development and launch risk by identifying and fixing adoption barriers while clinical design can still be adjusted. We integrate payer, prescriber, and patient reality into your Target Product Profile, endpoints, value story, and go‑to‑market plan. The outcome? Forecasts that reflect how the market will actually behave, not just how you hope it will.
OUR
WORK
We help life sciences companies see their products through the customers' eyes so they can succeed where it matters most.
At Litmys, the products we support don’t just launch. They resonate with physicians, payers, and patients.
OUR
SERVICES
Where We Change the Curve - Services That Move Decisions
Using proprietary frameworks and proven methodologies, Litmys helps clients overcome adoption barriers and achieve market success. Reach out to discuss how Litmys can support your product’s current stage and readiness needs.
OPPORTUNITY ASSESSMENT &
VALUATION
Litmys' approach is bottoms up. We estimate potential based on who will actually adopt a product, for which patients, and at what pace.
NEW PRODUCT COMMERCIAL READINESS
Our RAMPx Model bridges development with the needs of the market, identifying what it will take a new product to be truly adoption ready at launch.
LAUNCH READINESS SUPPORT
Ready on day one! Litmys crafts product positioning, messaging, and segmentation to ensure strong market uptake at launch and sustained momentum afterward.
BRAND
REVENUE
ACCELERATION
Taking a 360° view of current demand and barriers, Litmys develops strategies to speed adoption and expand penetration to achieve peak revenues faster.
THE
RAMPx MODEL
How We Quantify Adoption
RAMPx™ is the first FICO-style scoring model that predicts a product’s commercial success before Phase 3 of a clinical trial with confidence.
​
By quantifying market viability early, RAMPx helps pharma, biotech, MedTech, and investment leaders make smarter decisions, reduce costly late-stage failures, and improve the industry’s ~5.6% R&D ROI by ensuring resources are focused on assets with true commercial potential.​​
WHAT LITMYS DELIVERS
Stronger Launches and Greater Success
Clinical Predictability: Fewer late-stage surprises and avoidable Stage 3 failures
Launch Momentum: Adoption obstacles are addressed pre-approval
Commercial Confidence: Higher odds of success with quantified adoption readiness
Actionable Outputs: Adoption scores, gap analysis, and a unified cross-functional plan
OUR
CLIENTS
At Litmys we help drive commercial success for companies from pharma to diagnostics, biotech to MedTech, US to global. Our track record has helped propel more than 50 companies towards success. Let’s discuss how we can help position your next product to succeed in a competitive market.
"Harris Kaplan and the Litmys team have made an incredible impact on my work to pitch for all kinds of financing rounds and closing large transactions. Their insights have helped me and so many. Keep up the great work to help move our field forward."
- David Esposito, CEO of ONL Therapeutics